Host response against SARS-CoV-2 infection is impacted by allosteric modulation of cholinergic and purinergic receptors

Kavli Affiliate: Jean-Pierre Changeux

| Authors: Victoire Perraud, Guilherme Dias de Melo, Marco Cecchini, Lauriane Kergoat, Julien Lannoy, Jean-Pierre Changeux, Hervé Bourhy and Florence Larrous

| Summary:

The COVID-19 pandemic has caused nearly 8 million deaths and a broad spectrum of clinical manifestations driven by dysregulated host inflammation, notably involving key signalling proteins IL-6, CXCL10, and CXCL5. We previously demonstrated that ivermectin (IVM) improves clinical outcomes and reduces the IL-6/IL-10 ratio in the lungs of SARS-CoV-2-infected hamsters. Here, combining high-throughput confocal microscopy and transcriptomics in human cell co-cultures and a hamster model, we dissected how IVM modulates host cells responses via α7nAChR and purinergic receptors. In vitro, IVM acted independently of α7nAChR, instead triggering a P2X4-dependent drop in intracellular ATP, rapidly upregulating CXCL10 in macrophages, and suppressing CXCL5 and IL-6. In vivo, however, α7nAChR antagonists abolished IVM’s clinical benefit, as did the P2X4 blocker BX430; moreover, whereas the orthosteric agonist EVP-6124 was ineffective, the positive allosteric modulators (PAMs) IVM and GAT-107 reduced lung pathology and anosmia. Thus, IVM operates through a dynamic, context-dependent interplay: P2X4 drives early innate responses in cellular systems including macrophages, whereas the situation in vivo is more complex with α7nAChR being essential for tissue protection. These data position selective PAMs and the CXCL10/CXCL5 axis as promising targets for host-directed therapy in COVID-19.

Author summary COVID-19 has killed millions of people worldwide, and much of its harm comes not from the virus itself but from the patient’s own immune response spiralling out of control. To understand how this inflammation is controlled, we used ivermectin (a well-known anti-parasitic drug) as a research tool, building on our earlier finding that it improved the health of SARS-CoV-2-infected hamsters. In human immune cells grown in the laboratory, ivermectin modulated an ATP-sensing receptor, protected these cells, and shifted the inflammatory signals they released. In infected hamsters, however, protecting the animals’ health and their sense of smell required both this receptor and a second one, which responds to acetylcholine, one of the body’s natural chemical messengers, while protecting the lungs relied in particular on this second receptor. These findings do not support treating patients with ivermectin. Rather, they map the machinery behind harmful inflammation and point to a promising path forward: purpose-built drugs that fine-tune the body’s immune response in COVID-19 and other inflammatory diseases.

Read More